Publications by authors named "Stacey Marden"

Claim this Profile
M
Mass Balance in Pharmaceutical Stress Testing: A Review of Principles and Practical Applications.
Stacey Marden, John M Campbell, Neal Adams, Ronan Coelho, Chris Foti

AAPS J· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective.
Todd Zelesky, Steven W Baertschi, Chris Foti, Leonardo R Allain, Steven Hostyn, Stacey Marden

J Pharm Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
James S Scott, Darren Stead, Bernard Barlaam, Jason Breed, Rodrigo J Carbajo, Stacey Marden

J Med Chem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Relevance of Solution Phase Stress Testing of Solid Dosage Form Drug Products: A Cross-Industry Benchmarking Study.
John M Campbell, Chris Foti, Chloe Wang, Neal Adams, Leonardo R Allain, Stacey Marden

J Pharm Sci· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experimental design, development and evaluation of extended release subcutaneous thermo-responsive gels for small molecules in drug discovery.
Divya Sharma, Faraj Atassi, Steve Cook, Stacey Marden, Jianyan Wang

Pharm Dev Technol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
James S Scott, Thomas A Moss, Amber Balazs, Bernard Barlaam, Jason Breed, Stacey Marden

J Med Chem· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88 Diffuse Large B-Cell Lymphoma.
James S Scott, Sébastien L Degorce, Rana Anjum, Janet Culshaw, Robert D M Davies, Stacey K Marden

J Med Chem· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis